Sangamo Therapeutics (SGMO) Competitors $0.72 -0.02 (-2.29%) As of 10:09 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SGMO vs. GERN, MYGN, LXRX, VSTM, RIGL, EBS, XOMA, VNDA, CDXS, and IRWDShould you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Geron (GERN), Myriad Genetics (MYGN), Lexicon Pharmaceuticals (LXRX), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), Emergent Biosolutions (EBS), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry. Sangamo Therapeutics vs. Its Competitors Geron Myriad Genetics Lexicon Pharmaceuticals Verastem Rigel Pharmaceuticals Emergent Biosolutions XOMA Royalty Vanda Pharmaceuticals Codexis Ironwood Pharmaceuticals Geron (NASDAQ:GERN) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability. Do analysts recommend GERN or SGMO? Geron currently has a consensus price target of $3.79, suggesting a potential upside of 167.54%. Sangamo Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 523.27%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Geron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Geron 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13Sangamo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Which has preferable earnings and valuation, GERN or SGMO? Sangamo Therapeutics has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeron$76.99M11.73-$174.57M-$0.13-10.88Sangamo Therapeutics$81.71M2.67-$97.94M-$0.29-2.49 Does the media refer more to GERN or SGMO? In the previous week, Geron had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 6 mentions for Geron and 4 mentions for Sangamo Therapeutics. Geron's average media sentiment score of 0.80 beat Sangamo Therapeutics' score of 0.40 indicating that Geron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sangamo Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in GERN or SGMO? 73.7% of Geron shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 7.4% of Geron shares are held by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, GERN or SGMO? Geron has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Is GERN or SGMO more profitable? Geron has a net margin of -53.52% compared to Sangamo Therapeutics' net margin of -77.48%. Geron's return on equity of -31.37% beat Sangamo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Geron-53.52% -31.37% -16.01% Sangamo Therapeutics -77.48%-293.05%-63.85% SummaryGeron beats Sangamo Therapeutics on 9 of the 16 factors compared between the two stocks. Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGMO vs. The Competition Export to ExcelMetricSangamo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$218.14M$3.36B$6.12B$10.64BDividend YieldN/A2.29%5.66%4.69%P/E Ratio-2.4922.1586.1127.75Price / Sales2.67419.64588.17183.92Price / CashN/A47.1938.3262.20Price / Book6.5610.3912.976.80Net Income-$97.94M-$52.40M$3.30B$275.97M7 Day Performance5.73%4.11%3.27%2.08%1 Month Performance35.77%15.96%10.12%9.09%1 Year Performance-12.55%33.37%83.41%36.72% Sangamo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGMOSangamo Therapeutics2.2225 of 5 stars$0.72-2.3%$4.50+523.3%-6.5%$218.14M$81.71M-2.49480News CoverageAnalyst ForecastGERNGeron2.5519 of 5 stars$1.28-5.2%$3.79+195.8%-67.1%$816.66M$164.45M-9.8570News CoverageAnalyst ForecastMYGNMyriad Genetics3.5765 of 5 stars$7.99-0.9%$12.45+55.9%-68.2%$743.43M$832.90M-1.872,700LXRXLexicon Pharmaceuticals2.5955 of 5 stars$1.55+9.9%$3.23+108.1%+0.6%$563.27M$58.43M-4.70140Positive NewsAnalyst ForecastGap UpVSTMVerastem2.9 of 5 stars$8.61-1.0%$13.29+54.3%+208.0%$529.90M$2.14M-2.6350Analyst ForecastRIGLRigel Pharmaceuticals3.7099 of 5 stars$28.90+1.3%$38.20+32.2%+88.0%$518.47M$179.28M5.34160Analyst ForecastEBSEmergent Biosolutions4.346 of 5 stars$9.16+0.1%$13.50+47.4%+12.1%$488.70M$812.50M3.742,420Analyst ForecastXOMAXOMA Royalty4.1105 of 5 stars$36.61-7.8%$69.50+89.8%+42.0%$442.54M$12.77M-23.6210Analyst ForecastVNDAVanda Pharmaceuticals4.109 of 5 stars$5.40-0.6%$16.50+205.6%+21.9%$319.08M$203.47M-4.78290Analyst ForecastCDXSCodexis3.0902 of 5 stars$2.69+5.9%$11.00+308.9%-13.3%$242.83M$59.35M-3.24250Analyst ForecastGap UpIRWDIronwood Pharmaceuticals4.4837 of 5 stars$1.48-4.5%$4.94+233.8%-58.0%$240.40M$351.41M-29.59220News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies GERN Alternatives MYGN Alternatives LXRX Alternatives VSTM Alternatives RIGL Alternatives EBS Alternatives XOMA Alternatives VNDA Alternatives CDXS Alternatives IRWD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SGMO) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.For the everyday American who's worked hard to build their nest egg, Trump preserved a IRS loophole that allow...American Hartford Gold | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
